Newsroom

Download PDF Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Announces Trial in Progress Poster Also Presented Highlighting Phase 3 TIVO-3 Study of Tivozanib in RCC CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 5, 2017– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc., co-development partners, today announced the presentation of results from

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 19, 2017– AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 16, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017. In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2017– The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer. “We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A. Termeer. Henri’s wisdom, foresight and persistence fundamentally changed our industry, which exists

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled “notch binding agents and antagonists and methods of use thereof.” Allowed under the application are composition of matter and method of use

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 4, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the resources to potentially fund operations through the readout of our pivotal, Phase 3 TIVO-3 study

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 20, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017. Among these is a Trials in Progress presentation highlighting the ongoing Phase 3, randomized, controlled, multi-center, open-label TIVO-3 study comparing tivozanib, the Company’s potent, selective,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 13, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization Application (MAA) for tivozanib as a first-line treatment for renal cell carcinoma. With submission of the response complete,